This course discusses the 2024 GOLD guideline and 2019 NICE guideline for COPD. More focus is given to symptom control and exacerbations, rather than deciding treatment based purely on the FEV1 value. The course focuses on the practical applications of these guidelines, giving audit ideas to find patients with undiagnosed COPD and ensure that treatment is up to date and evidence based.
An educational grant was received by Pfizer Limited for the production of the course. Editorial and content decisions were made solely by the RCGP.
Curriculum: Respiratory Health
CPD Points: 0.5
Time to complete this course: 30 minutes
Date of publication: 15 May 2018
Reviewed and updated: 15 January 2022
Mode: Course
Remove from search results: No
Podcast icon: No
Course index: Show
Section titles: Hide